New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For RPRX From The Last 14 Days
Check below for free stories on RPRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 22, 2014
11:05 EDTRPRXPiper Jaffray biopharm analyst holds an analyst/industry conference call
Subscribe for More Information
09:01 EDTRPRXRepros Therapeutics has favorable near-term catalysts, says BofA/Merrill
BofA/Merrill lowered Repros Therapeutics' price target to $27 from $32 due to competitive pricing and a contraction in the TRT market but says it expects favorable near-term data from Androxal and AndroGel studies. The firm expects the Sept 17 FDA meeting to access DV risks from exogenous testosterone to be favorable. Shares are Buy rated.
August 11, 2014
09:19 EDTRPRXRepros Therapeutics reports Q2 EPS (38c), consensus (39c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use